22 May 2013
Keywords: EU Commission, Lundbeck, Antitrust, Citalopram
Article | 07 January 2010
As part of its ongoing questioning of the activities of European pharmaceutical companies, which have, over the past, included “dawn ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 January 2010
21 May 2013
© 2013 thepharmaletter.com